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Abstract 
Gamma-Knife became an established 
therapeutic alternative for selected cases of 
vestibular schwannomas (benign tumors 
rooting from Scwann cells of vestibular 
nerve). However, the long term results and 
effects on the tumor and surrounding brain 
are still a matter of research. We analyze the 
imagistic findings in the patients with 
vestibular scwannomas treated with 
gamma-knife radiosurgery in the Gamma-
Knife Department, Hygeia Hospital, 
Athens.  
We performed radiosurgery on 79 cases 
of vestibular scwannomas. 23 of them were 
first operated with incomplete resection and 
had gamma-knife performed on residual 
tumor. Of all cases, one patient died 4 years 
after the treatment, while 4 cases didn’t 
comply with the follow-up protocol and 
were excluded from the study. The other 
cases underwent a follow-up protocol with 
MRI sudies at 6, 12, 18, and 24 months 
following the gamma-knife session. We 
looked at the tumoral volume, and the 
evolution of the tumor in relationship with 
the iradiation dise and isodose curve.  
Our results confirm the landmark 
results of Karolinska an Pittsburg studies. 
We show that small gamma-knife doses are 
suitable for a satisfactory control of tumoral 
volume. Stereotactic MRI imaging and 
multiple doses programs are the main 
factors contributing to these results.  
Keywords: vestibular schwannoma, 
radiosurgery, gamma-knife, MRI 
Introduction 
Histologically, vestibular schwannomas 
are benign tumors that grow from the 
Schwann cells of the 8th cranian nerve. 
Due to improved neuroimaging the 
incidence of vestibular schwannomas 
within the general population increased.  
However, despite the advances in 
introperatory techniques, surgery still 
carries a risk for morbidity and moratality. 
Depending on tumors characteristics 
vestibular schwannomas can be treated by 
different methods, other than 
neurosurgery. Radiosurgery is one of these 
non-invasive techniques that can be used to 
treat vestibular schwannomas. It uses 
gamma radiation (photons) and is known as 
“Gamma-Knife” or “γ-Knife”.  
We analyze the imagistic findings in the 
patients with vestibular scwannomas treated 
with gamma-knife radiosurgery in the 
Gamma-Knife Department, Hygeia 
Hospital, Athens. 
Our results point to the fact that using 
small doses of radiation (similar to those 
used in the reference series from Karolinska 
and Pittsburg) can control the volume of 
the lesion as shown by the follow-up 
controls results. Stereotactic MRI and a 
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multiple dosage program seem to be the 
main factors in achieving this result. 
According to published results the method 
can fail if the doctor decides not to partially 
exclude the lesions localized ar superior 
limit of the treated region. 
Materials and method 
In the last six years (February 2004 – 
September 2010) 79 cases of vestibular 
schwannomas have been treated with 
gamma-knife radiosurgery in our unit. 23 
patients  have undergone surgery prior to 
gamm-knife, and had radiosuergery as an 
adjuvant therapy on remnant tumor. One 
patient died 4 years after the gamma-knife 
treatment because of pre-existing cardiac 
co-moribidities. 4 patients failed to comply 
woth the follow-up rpotocol and were 
excluded from our study. 2 patients 
declaired that their quality of life 
deteriorated as a result of radiosurgery. 
To study the effects of radiation therapy 
the patients had to comply with a follow-up 
protocol that included MRI studies at 6, 12, 
18, and 24 months after the treatment. The 
goal of follow-up was to monitor the 
volume of the schwannoma and to analyze 
the imagistic aspects as a result of gamma-
knife therapy. The radiation dose (Gy) and 
radiation isodose curve have been measured 
in relationshipwith their effect in controling 
the progress of the tumors. 
The average age of the patients included 
in our study was 55 years (22-74). Out of 
79 cases 9 presented intracanlicular tumors, 
19 developed intracanalicular and cisternal 
tumors, while 51 presented with tumors 
occupying the cerebello-pontine cistern 
(table 1.). the main tumor volume (Vm) 
was 4.72 cm3 (0.2-19.3 cm3). The female to 
male ration was 51:28. 
 
TABLE 2 
Characteristics of the 79 vestibular 
schwannoma patients that underwent 
gamma-knife surgery 
 
Parameters Values 
Median age (interval) 55 (27 - 74) 
Female to male ratio 51:28 
Tumor localization 
        intracanalicular 
        cerebello-pontine cistern 
        both cisternal and      
        intracanalicular 
 
9 
51 
19 
Previously treated 23 
Medium colume in cm3 
(interval) 
4,72 (0,20-
19,3) 
 
Gamma-knife therapy particularities 
Gamma-knife radiosurgery is base on 
four principles: 
1. “Target” localization, using neuro-
imagistic techniques, a stereotactic frame, 
and computer software to record and alter 
imaging data. 
2. Computing lesion volume 
3. Determining the distribution of 
radiation dose 
4. Radiotherapy 
During a radiosurgery session the 
median of isodose curve was 48.25%, with 
an interval of 40-54%. 
Target localization is extremely 
important and excluding important cranial 
structures from being exposed to the 
gamma radiation (such as cranial nerves, 
cerebellum, and of course brain stem). 
During treatment average marginal dose 
was 12.09 Gy (11 – 14 Gy), and maximal 
average dose was 19.83 Gy (20.5 – 29.9 Gy). 
Average tumor volume of treated 
 
 
 
Charalampos Seferis          Imaging of vestibular schwannomas following γ-Knife treatment 
 
 
 
schwannomas was 4.72 cm3  (0.2 – 19.3 
cm3). 
To protect the undefined segments of 
the facial and trigeminal nerves that are 
prone to be included in the designated 
lesion volume, we administered in these 
areas doses below 13 and 15 Gy 
respectively. In two cases where the tumor 
had an occupying effect involving the 
brainstem the same dose didn’t reach more 
than 10 Gy. All patients responded well to 
the treatment and were released the next 
morning after treatment completion. None 
reported neurological problems during 
hispitalization (such as epileptic seizures). 
Headache was present in 12 cases, most 
likely due to the steretactic frame. To 
address these headaches patients were given 
oral pain killers for a short period of time 
(2-3 days) in the period following their 
release. 
Follow-up 
All patients, with one exception, 
underwent MRI imaging 6 months after the 
treatment. Six of them didn’t present for 
the next follow-up session, at 12 months. 
MRI evaluation criteria included: 
•Changes in the volume of the 
vestibular schwannoma 
•Neuro-imagistic findings like: loss of 
central enhance (necrosis), local swelling 
through the cerebral ventricular system. 
Results 
The average follow-up period was of 24 
months (1 – 51). 84.2% of the patients 
performed at least one MRI exploration at 6 
months.  
MRI evaluation 
The solid part of the tumor reacted 
satisfactory to gamma-knife iradiation. As 
documented by the MRI images in the first 
six months this response takes the shape of 
a central region of necrosis (seen in T1). 
Acording to published data this phenomena 
is noticed from the first month  (or later 
than 23 months) and can extend within the 
tumor in the next 10 months (or even later 
than 60 months) after the treatment. A 
small percentage of the patients (11,8%) 
showed a swelling of the lesion. MRI 
findings at first follow-upmatch those 
reported in the literature in 34 cases. Only 2 
cases showed a significant change in lesion 
volume in the 24 months period following 
gamma-knife therapy (from 0.71 cm3 to 1.1 
cm3, and from 19.3 cm3 to 23.1 cm3), while 
the maximum reduction in tumor volume 
recorded in our series was from 12.4  to 2.7 
cm3. 
Discussion 
Optimal radiation dosage for tumor control  
Optimal radiation dosage for vestibular 
schwannoma control is still a matter of 
debate. A review of the literature showed a 
tendency to decreasing prescription dosage 
from 25-100 Gy used in the initial studies 
to 13 Gy in the current protocols. Nóren, et 
al. have prescribed dosages of 25-35 Gy to 
the tumor periphery to ensure stopping 
tumor growth. However, high dose 
radiation has led to high morbidity due to 
facial and trigeminal nerve damage. In 
addition, possible preservation of hearing 
may be compromised when using a high 
dosage. First of all, a reduced radiation dose 
lowers the probability of cranial nerve 
neuropathy. Second of all, small doses have 
a better chance, at least in theory, to 
preserve hearing close to preoperative 
levels. Third of all, a lower dose should 
theoretically reduce or minimize the degree 
of swelling of the tumor that may occur 
after treatment.  
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Figure 1 Left: Male, 62 yrs. Old, before therapy. Dose 12Gy (45%), volume 3,4 cm³.  
Right: control at 6 months (central necrosis) 
 
  
 
  
Figure 2 Upper left: Male, 73 yrs., before therapy. Dose 11 Gy, tumor volume 5.6 cm³. 
At 24 months after gamma-knife tumor volume 3,1 cm³ (lower right). Dimensions before therapy:  
3 cm x 2 cm, and after therapy: 2 cm x 1,4 cm. 
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Figure 3 Female, 44 yrs., before therapy. Dose 11 Gy (50%). After 6, 12, and 24 months respectively.   
Tumor volume before therapy  12,4 cm³, 24 months after therapy 3cm³. 
 
Larson et al. proposed the use of a single 
dose of 13.5 Gy, given the biological effect 
of delayed tissue response. Flickinger and 
ass. have questioned whether or not the 
tumor control rate could be reduced by a 
dose smaller than 13 Gy. In this study, we 
had satisfactory results in patients treated 
with a median marginal dose of 12.09 Gy 
(11-14 Gy). Thus, in our experience it is 
possible to obtain satisfactory long-term 
control of the tumor at a marginal dose less 
than 11 Gy. Tumor control rate was in no 
way worse than those reported in earlier 
series, where significantly higher doses 
were used. 
Optimal dosage for preservation of cranial 
nerves 
It has been suggested that the facial 
nerve tolerates marginal doses up to 15 Gy, 
but doses above 14 Gy have been shown to 
lead to a significant increase in neuropathy 
incidence, particularly in the patients with 
large tumors. In the early days of 
radiosurgery, subjective numbness or 
hypoesthesia has been reported as major 
complication of trigeminal nerve radiation 
damage. The incidence was as high as 19% 
in both Karolinska and Pittsburgh series. 
The large tumoral volume and high 
radiation doses used corroborate to this 
undesirable consequence of radiation 
therapy. The incidence of trigeminal 
neuropathy was reduced to 4% transient 
neuropathy and 1.6% persistent neuropathy 
in Charlottesville exerience, where the 
average marginal dose used was 13.2 Gy. In 
the present series, no patient developed any 
kind of sensory deficit. Preservation of 
hearing has become the main concern in 
advanced radiosurgery. In this study, 43 of 
60 patients with good preoperative hearing, 
maintain a functional hearing during a 
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follow-up period of 21 months. Numerous 
studies have reported a total rate of 33-55% 
of hearing preservation in a 2-4 years period 
after treatment. A definite inverse 
correlation exists between the dimensions 
of the tumor and the probability of hearing 
preservation. Prasad and colleagues have 
reported a marginal inverse correlation 
between the dose used and the likelihood of 
hearing preservation, especially manifest  at 
a dose higher than 13 Gy. In our series, 
neither the volume of the tumor nor the 
marginal dose appear to play a critical role 
in postoperative hearing preservation. In 
contrast, pure tone audiometry before 
Gamma Knife surgery seems to be a good 
possible measure for evaluating the results.  
Loss of central contrast enhance  
Loss of central enhancing on MRI 
imaging was observed in 54% of patients of 
Prasad et al., 70% of Nóren, et al. and 63% 
of Flickinger, et al series. In this study, this 
phenomenon was observed in 63.3% of 
cases. This is a common observation after 
radiosurgery. More research is required to 
clarify the  pathogenesis. Backlund reported 
that tumor necrosis was found in a 
histological study, which corresponds to the 
central region of enhanced MRI image. 
Seo, et al. showed using scanning with 
99Tc (human serum albumin - 
dietulenetriamin pentaacetic acid-photon) 
positron emission computed tomography 
reduced vascularization of vestibular 
schwannoma 1 to 2 years after 
radiosurgery,. Spiegelman and colleagues 
have suggested that ischemia was produced 
by tumor associated acute edema. Fukoka 
and colleagues suggested that apoptosis may 
be a possible mechanism. Based on these 
observations, it is aceeptable to consider 
that the loss of radiological central 
enhancing is a reliable indicator of long-
term good control. This hypothesis, 
however, requires additional data from 
more patients and longer-term follow-up. 
Failed treatment 
In no case was there any evidence of 
active tumor growth. It has to be considered 
that labyrinth schwanomas can swell 
without regrowing after radiosurgery. It is 
suggested that the modest doses currently 
in use may reduce this tendency.   
Conclusions 
Using small doses of radiation (similar 
to those used in the reference series from 
Karolinska and Pittsburg, smaller than the 
usual doses used in other gamma-knife 
units) can control the volume of the lesion 
as shown by the follow-up controls results. 
Stereotactic MRI and a multiple dosage 
program seem to be the main factors in 
achieving this result. According to 
published results the method can fail if the 
doctor decides not to partially exclude the 
lesions localized ar superior limit of the 
treated region. 
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